On Thursday, Emcure Pharmaceuticals announced a significant step forward in HIV treatment access through a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a subsidiary of Gilead Sciences based in California. This collaboration will allow Emcure to manufacture and supply generic versions of lenacapavir,